Marked disparity between age‐related changes in dopamine and other presynaptic dopaminergic markers in human striatum
暂无分享,去创建一个
John W Haycock | Yoshiaki Furukawa | J. Haycock | S. Kish | O. Hornykiewicz | L. Becker | L. Ang | Y. Furukawa | Stephen J Kish | Oleh Hornykiewicz | Laurence Becker | Lee Ang
[1] V. Tsang,et al. Optimum dissociating condition for immunoaffinity and preferential isolation of antibodies with high specific activity. , 1991, Journal of immunological methods.
[2] L. Cote,et al. Biochemical changes in normal aging in human brain. , 1983, Advances in neurology.
[3] E. Hirsch,et al. New Species of Human Tyrosine Hydroxylase mRNA Are Produced in Variable Amounts in Adrenal Medulla and Are Overexpressed in Progressive Supranuclear Palsy , 1996, Journal of neurochemistry.
[4] N. Volkow,et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging , 1998, Annals of neurology.
[5] A. Levey,et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease , 1996, Neurology.
[6] A. Levey,et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users , 1996, Annals of neurology.
[7] I. Black,et al. Postmortem changes in brain catecholamine enzymes. , 1975, Archives of neurology.
[8] S. Kish,et al. Influence of development and aging on brain biopterin , 1998, Neurology.
[9] T. Bonner,et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. Langston,et al. Aging and the nigrostriatal dopamine system: a non-human primate study. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[11] P. Yates,et al. The effects of ageing on the pigmented nerve cells of the human locus caeruleus and substantia nigra , 1979, Acta Neuropathologica.
[12] R. Surtees,et al. Aromatic L‐amino acid decarboxylase deficiency , 1992, Neurology.
[13] L. Naudon,et al. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain , 2000, Neuropharmacology.
[14] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[15] O. Hornykiewicz,et al. OCCURRENCE AND DISTRIBUTION OF AROMATIC l‐AMINO ACID (l‐DOPA) DECARBOXYLASE IN THE HUMAN BRAIN , 1972, Journal of neurochemistry.
[16] S. Kish,et al. Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.
[17] M. Goldin,et al. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones , 1998 .
[18] D. Rosenberg,et al. Changes in the dopaminergic innervation of monkey prefrontal cortex during late postnatal development: A tyrosine hydroxylase immunohistochemical study , 1994, Biological Psychiatry.
[19] J. Haycock,et al. Striatal 3,4‐dihydroxyphenylalanine decarboxylase in aging: Disparity between postmortem and positron emission tomography studies? , 1995, Annals of neurology.
[20] D. Rosenberg,et al. Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: A tyrosine hydroxylase immunohistochemical analysis , 1995, The Journal of comparative neurology.
[21] J Tauscher,et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] Y. Agid,et al. Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.
[23] R. Floyd. Antioxidants, oxidative stress, and degenerative neurological disorders. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[24] K. Frey,et al. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. , 1995, European journal of pharmacology.
[25] J. Kleinman,et al. Decreased density of human striatal dopamine uptake sites with age. , 1986, European Journal of Pharmacology.
[26] P. Mcgeer,et al. Aging and extrapyramidal function. , 1977, Archives of neurology.
[27] M. Caron,et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. , 1992, Molecular pharmacology.
[28] K. Titani,et al. Isolation and characterization of a cDNA clone encoding human aromatic L-amino acid decarboxylase. , 1989, Biochemical and biophysical research communications.
[29] J. C. Stoof,et al. [123I]β-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls , 1997, European Journal of Nuclear Medicine.
[30] A. Rajput,et al. Age, environments, and the number of substantia nigra neurons. , 1990, Advances in neurology.
[31] D. Mash,et al. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. , 1994, The Journal of pharmacology and experimental therapeutics.
[32] Kremzner Lt,et al. Biochemical changes in normal aging in human brain. , 1983 .
[33] G. Di Chiara. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. , 1995, Drug and alcohol dependence.
[34] P. Seeman,et al. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.
[35] V. Tennyson,et al. The developing neostriatum of the rabbit: correlation of fluorescence histochemistry, electron microscopy, endogenous dopamine levels, and ( 3 H)dopamine uptake. , 1972, Brain research.
[36] D. Sparks,et al. Synaptic Neurochemistry of Human Striatum During Development: Changes in Sudden Infant Death Syndrome , 1993, Journal of neurochemistry.
[37] J. Haycock,et al. Elevated Tyrosine Hydroxylase in the Locus Coeruleus of Suicide Victims , 1994, Journal of neurochemistry.
[38] J S Fowler,et al. Decreased dopamine transporters with age in healthy human subjects , 1994, Annals of neurology.
[39] P. Davies,et al. REGIONAL DISTRIBUTION OF MONOAMINES AND THEIR METABOLITES IN THE HUMAN BRAIN , 1978, Journal of neurochemistry.
[40] G. Chiara. The role of dopamine in drug abuse viewed from the perspective of its role in motivation , 1995 .
[41] J. Haycock. Multiple Forms of Tyrosine Hydroxylase in Human Neuroblastoma Cells: Quantitation with Isoform‐Specific Antibodies , 1993, Journal of neurochemistry.
[42] J. Haycock. Four Forms of Tyrosine Hydroxylase Are Present in Human Adrenal Medulla , 1991, Journal of neurochemistry.
[43] G. Gopinath,et al. Developing substantia nigra in human: a qualitative study. , 1994, Developmental neuroscience.
[44] R A Koeppe,et al. Imaging the vesicular monoamine transporter. , 2001, Advances in neurology.
[45] M. Wolf,et al. Effect of Aging on Tyrosine Hydroxylase Protein Content and the Relative Number of Dopamine Nerve Terminals in Human Caudate , 1991, Journal of neurochemistry.
[46] J. Haycock. Quantitation of tyrosine hydroxylase, protein levels: spot immunolabeling with an affinity-purified antibody. , 1989, Analytical biochemistry.
[47] J. Haycock,et al. Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy , 1995, Movement disorders : official journal of the Movement Disorder Society.
[48] P. Fitzpatrick,et al. Tetrahydropterin-dependent amino acid hydroxylases. , 1999, Annual review of biochemistry.
[49] H. Ehringer,et al. Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems , 2005, Klinische Wochenschrift.
[50] S. Leff,et al. Age‐related decreases in GTP‐cyclohydrolase‐I immunoreactive neurons in the monkey and human substantia nigra , 2000, The Journal of comparative neurology.
[51] O. Hornykiewicz,et al. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.
[52] L. Iversen,et al. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. , 1974, Brain : a journal of neurology.
[53] Y. Agid,et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. , 2000, Brain : a journal of neurology.
[54] H. Haug,et al. Morphometry of the human cortex cerebri and corpus striatum during aging , 1991, Neurobiology of Aging.
[55] P. Mcgeer,et al. Age Changes in the Human for Some Enzymes Associated with Metabolism of Catecholamines, GABA and Acetylcholine , 1975 .
[56] T. Sourkes,et al. Monoamine metabolism in human brain. , 1977, Archives of General Psychiatry.
[57] F. Carroll,et al. Striatal [125I]RTI-55 binding sites in cocaine-abusing humans , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[58] J. Marcusson,et al. Age-correlated loss of dopamine uptake sites labeled with [3H]GBR-12935 in human putamen , 1989, Neurobiology of Aging.
[59] A. Levey,et al. Postnatal development of tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in monkey rostral entorhinal cortex. , 1998, Cerebral cortex.
[60] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[61] S. Gilman,et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.
[62] P. Greengard,et al. Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[63] N. Volkow,et al. Dopamine transporters decrease with age. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[64] P. Mcgeer,et al. Distribution of tyrosine hydroxylase activity in adult and developing brain. , 1967, Canadian journal of biochemistry.
[65] M. Bannon,et al. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[66] J. Haycock,et al. Four isoforms of tyrosine hydroxylase are expressed in human brain , 1993, Neuroscience.
[67] S. Leach,et al. Elimination of nonspecific adsorption of serum proteins by Sepharose-bound antigens. , 1978, Analytical biochemistry.
[68] Janet R. Saffer,et al. Effects of age on dopamine transporters in healthy humans. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[69] L. Iversen,et al. Huntington's Chorea , 1974 .
[70] G. Duncan,et al. Cocaine use increases [3HWIN 35428 binding sites in human striatum , 1993, Brain Research.
[71] Y. Yoshida,et al. Alterations of tetrahydrobiopterin biosynthesis and pteridine levels in mouse tissues during growth and aging , 2000, Brain and Development.
[72] W. Gibb,et al. Dopa‐responsive dystonia: Pathological and biochemical observations in a case , 1994, Annals of neurology.
[73] S J Kish,et al. Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self- administration , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[74] P. Gaspar,et al. Regional Distribution of Neurotransmitter Synthesizing Enzymes in the Basal Ganglia of Human Brain , 1980, Journal of neurochemistry.
[75] K. Y. Little,et al. 425. Cocaine effects on striatal dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) protein in humans , 2000, Biological Psychiatry.
[76] INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .
[77] J. Cano,et al. Chronic inhibition of the high-affinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra. , 1997, Free radical biology & medicine.
[78] J. Haycock. Species differences in the expression of multiple tyrosine hydroxylase protein isoforms , 2002, Journal of neurochemistry.
[79] J. Haycock. Polyvinylpyrrolidone as a blocking agent in immunochemical studies. , 1993, Analytical biochemistry.
[80] S. Kish,et al. The Vesicular Monoamine Transporter, in Contrast to the Dopamine Transporter, Is Not Altered by Chronic Cocaine Self-Administration in the Rat , 1996, The Journal of Neuroscience.
[81] P. K. Smith,et al. Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.
[82] B. Winblad,et al. Post-mortem distribution of dopamine and homo-vanillic acid in human brain, variations related to age, and a review of the literature , 2005, Journal of Neural Transmission.
[83] P. Mcgeer,et al. ENZYMES ASSOCIATED WITH THE METABOLISM OF CATECHOLAMINES, ACETYLCHOLINE AND GABA IN HUMAN CONTROLS AND PATIENTS WITH PARKINSON'S DISEASE AND HUNTINGTON'S CHOREA , 1976, Journal of neurochemistry.